


PTO/SB/CBA (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/749,630
				Filing Date	12-31-2003
				First Named Inventor	KLEEMANN
				Group Art Unit	1614
				Examiner Name	
				Attorney Docket Number	DEAV2002/0095 - US - CNT

[illegible][illegible]

Examiner Signature		Date Considered	4/23/05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/CSS (10-96)
Approved for use through 10/31/99. OMB C651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/749,630
				Filing Date	12-31-2003
				First Named Inventor	KLEEMANN
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	DEAV2002/0095 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		EVERETT, Chris, Haemolytic disease of the newborn - time to prevent unnecessary deaths, Comparative Medicine, The British Journal of General Practice, 2000, 50 (5), pg. 511	
		HOWITZ, et al., Uber O, p- und ana-Jodchinolin und deren Derivate, Justus Liebig's Ann. Chem. (1913), 396, pgs. 53-75	
		SCHULTHEIS, Patrick, et al., Targeted Disruption of the Murine Na ⁺ /H ⁺ Exchanger Isoform 2 Gene Causes Reduced Viability of Gastric Parietal Cells and Loss of Net Acid Secretion, J. Clin. Invest., 1998, 101 (6), pps. 1243-1253	
		SUI, Z. et. al., A Convenient Synthesis of 3,5-Bis(Trifluoromethyl) Salicylic Acid, Synthetic Communications, 1997, 27(20), pp.3581-3590	
		TOYOTA, Masahiro, et al., Tandem Michael Addition-[3,3] Sigmatropic Rearrangement Processes, Part 2. Constuction of Cyclopropa [3,4] pyrrolo [3,2-e] indol-4-one (CPI) Unit of Antitumour Antibiotic CC-1065, J. Chem. Soc. Perkin Trans. 1, (1992), (5), pgs. 547-552	

Examiner Signature		Date Considered	10/23/05
-----------------------	--	--------------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPFP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.